Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies

Expert Review of Anticancer Therapy

Volumn 3, Issue 2, 2003, Pages 167-178

  Pasetto, Lara Maria ^a   Basso, Umberto ^a   Brandes, Albe Ariela ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Chemotherapy; High dose chemotherapy; Soft tissue sarcoma; Toxicity

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAELIX; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IDARUBICIN; IFOSFAMIDE; IMATINIB; MELPHALAN; MESNA; MITOXANTRONE; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PHARMOORUBICIN; RAZOXANE; SEMAXANIB; TEMOZOLOMIDE; TRABECTEDIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; AUTOTRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROTECTION; CLINICAL TRIAL; CORRELATION FUNCTION; CYSTITIS; DERMATITIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; METHODOLOGY; MUCOSA INFLAMMATION; MUSCLE CRAMP; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PERIPHERAL EDEMA; REVIEW; SKIN TOXICITY; SOFT TISSUE SARCOMA; STANDARD; STEM CELL TRANSPLANTATION; TUMOR BLEEDING;

EID: 0037394273     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.2.167     Document Type: Review

References (69)

1. American Cancer Society: Cancer Facts and Figures (1995). American Cancer Society, Atlanta, GA, USA (1995).
2. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 13, 1600-1608 (1995).
3. Andriole GL, Sandlund JT, Miser JS. The efficacy of MESNA (2-mercaptoethane sodium sulphonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J. Clin. Oncol. 5, 799-785 (1987).
4. Cerny T, Castiglione M, Brunner K et al. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1, 175-177 (1990).
5. Le Cesne A, Judson I, Crowther D et al. Randomized Phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 18, 2676-2684 (2000).
6. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717 (1979).
7. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Sem. Oncol. 25(4), 10-14 (1998).
8. Meinardi MT, vad der Graaf WTA, van Veldhuisen DJ, Gietema JA, de Vries EGE, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat. Rev. 25, 237-247 (1999).
9. Legha S, Benjamin R, Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous iv. infusion. Ann. Intern. Med. 96, 133-139 (1982).
10. Lipshultz SE, Giantris AL, Lipsitz SR et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic protocol. J. Clin. Oncol. 20, 1677-1682 (2002).
11. Dardir M, Herman E, Ferrans V. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneous hypertensive rats. Cancer Chemother. Pharmacol. 23, 269-275 (1989).
12. Penco S, Casazza A, Franchi G. Synthesis, antitumor activity and cardiac toxicity of new 4-demethoxy-anthracyclines. Cancer Treat. Rep. 67, 665-673 (1983).
13. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat. Rev. 19, 197-228 (1993).
14. Mouridsen HT. New cytotoxic drugs in the treatment of breast cancer. Acta Oncol. 29, 343-347 (1990).
15. Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br. J. Cancer 78(12), 1634-1639 (1998).
16. Muggia F, Hainsworth J, Jeffers S. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15, 987-993 (1997).
17. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin-rationale for use in solid tumors. Drugs 54(S4), 15-21 (1997).
18. Hu YP, Jarillon S, Dubernet C. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother. Pharmacol. 37, 556-560 (1996).
19. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol. 13, 177-1785 (1995).
20. Garcia AA, Kempf RA, Rogers M, Muggia FM. A Phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann. Oncol. 9, 1131-1133 (1998).
21. Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R. Liposomal doxorubicin (Caelix) in advanced pretreated soft tissue sarcomas (STS): a Phase II trial of the Italian Sarcoma Group (ISG). Anticancer Res. 20, 485-492 (2000).
22. Skubitz KM. A Phase II trial of pegylated liposomal doxorubicin (Doxil) demonstrates activity in refractory sarcoma, mesotelioma and head and neck cancer. Am. Soc. Clin. Oncol. 18, 541 (1999).
23. Judson I, Radford J, Blay JY. Randomized Phase II trial of pegylated liposomal doxorubicin (Doxil/Caelyx) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomas: a study by the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Eur. J. Cancer 37(7), 870-877 (2001).
24. Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J. Clin. Oncol. 15, 2111-2117 (1997).
25. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Sem. Oncol. 25(4), 10-14 (1998).
26. Sharpe HBA, Field EO, Hellman K. Mode of action of the cytostatic agent ICRF-159. Nature 226, 524-526 (1970).
27. Speyer JL, Gren MD, Zeleniuch-Jacquotte A. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10, 117-127 (1992).
28. Kemp G, Rose P, Lurain J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14, 2101-2112 (1996).
29. Gregg RW, Molepo M, Monpetit V. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurologic tissues and morphologic evidence of toxicity. J. Clin. Oncol. 10, 795-803 (1992).
30. Herman EH, Zhang J, Chadwick DP, Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 45, 329-334 (2000).
31. Boccia RV, Alster M, Houskamp E. Amifostine (Ethyol) given by rapid iv. push is safe and tolerable. Am. Soc. Clin. Oncol. 20, 2953 (2001).
32. Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J. Clin. Oncol. 18(8), 1764-1770 (2000).
33. Johnston EM, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Sem. Oncol. 25, 552-561 (1999).
34. Savarese DMF, Chung-Chang H, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with haematologic malignancies and solid tumors. J. Clin. Oncol. 15, 2981-2995 (1997).
35. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus cyvadic versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the EORTC/STBSG. J. Clin. Oncol. 13, 1537-1545 (1995).
36. Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11, 1276-1285 (1993).
37. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11, 1269-1275 (1993).
38. Steward WP, Verweij J, Somers R et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the EORTC/STBSG. J. Clin. Oncol. 11, 15-21 (1993).
39. Palumbo R, Neumaier C, Cosso M et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a Phase II study. Eur. J. Cancer 35, 66-72 (1999).
40. Frustaci S, Buonadonna A, Galligioni E et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J. Clin. Oncol. 15, 1418-1426 (1997).
41. Lopez-Pousa A, Buesa J, Del Muro GJ et al. Sequential high-dose doxorubicin and high-dose ifosfamide in advanced previously untreated soft tissues sarcomas of the adult (STS). A multicenter Phase II study of the Spanish Group for Research on Sarcomas (GEIS). Am. Soc. Clin. Oncol. 20, 1409 (2001).
42. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Co-operative Trial. J. Clin. Oncol. 19(5), 1238-1247 (2001).
43. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J. Clin. Oncol. 8, 3643-3650 (2000).
44. Falk MH, Hiddeman W, Kolb HJ et al. High dose chemotherapy with peripheral blood stem cell rescue as consolidation treatment for adult patients with chemosensitive metastatic soft tissue sarcomas. Am. Soc. Clin. Oncol. 20, 1442 (2001).
45. Montemurro F, Grosso F, Ferrante P, Rosti G, Aglietta M. High-dose chemotherapy with hematopoietic blood stem cell transplant (HDCT/HSCT) for soft tissue sarcoma (STS) of the adult: analysis of the European Group of Blood and Marrow Transplantation (EBMT) registry. Am. Soc. Clin. Oncol. 20, 1448 (2001).
46. Howson-Jan K, Hotte SJ, Tenhaff D, Bramwell VH. High-dose chemotherapy (HDCT) and bone marrow transplant (BMT) in patients with advanced sarcoma: experience of a Canadian institution. Am. Soc. Clin. Oncol. 20, 1452 (2001).
47. Grunewald R, Abbruzzese JL, Tarassoff P et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 27, 258-262 (1991).
48. Patel SR, Gandhi V, Jenkins J et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol. 19(15), 3483-3489 (2001).
49. Casper ES, Waltzman RJ, Schwartz GK et al. Phase II trial of paclitaxel in patients with soft tissue sarcoma. Cancer Invest. 16(7), 442-446 (1998).
50. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1380, 2034-2037 (1999).
51. Joensuu H, Roberts PJ, Sarlomo-Mikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344(14), 1052-1056 (2001).
52. Druker BJ. STI 571: a paradigm for clinical trials of molecularly targeted agents. Am. Soc. Clin. Oncol. 20, 419-425 (2001).
53. Blanke CD, von Mehren M, Joensuu H et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI 571, in patients with unresectable or metastatic gastrointestinal stromal tumor (GISTs) expressing c-kit (CD117). Am. Soc. Clin. Oncol. 20, 1 (2001).
54. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumors: a Phase I study. Lancet 358, 1421-1423 (2001).
55. Woll PJ, Judson I, Lee SM et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 35, 410-412 (1999).
56. Del Muro XG, Pousa AL, Buesa JM et al. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma (STS): a Phase II trial of the Spanish Group for Research on Sarcomas (GEIS). Am. Soc. Clin. Oncol. 20, 1412 (2001).
57. Erba E, Bergamaschi D, Bassano L et al. Ecteinascidin-743 (ET743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37, 97-105 (2001).
58. Delaloge S, Yovine A, Taamma A et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J. Clin. Oncol. 19, 1248-1255 (2001).
59. Takahashi N, Li WW, Banerjee D et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin-743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin. Cancer Res. 7, 3251-3257 (2001).
60. Lopez-Martin JA, Nieto A, Demetri GD et al. Safety profile of ecteinascidin-743 (ET-743) in Phase II clinical trials (CT) in adult patients with solid tumors. Am. Soc. Clin. Oncol. 21, 96 (2002) (Abstract 382).
61. Laverdiere C, Kolb A, Meyers P et al. Phase II study of ET-743 in recurrent osteosarcoma. Am. Soc. Clin. Oncol. 21, 96 (2002) (Abstract 383).
62. Demetri GD. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 13(Suppl. 1), 7-9 (2002).
63. Fujiwara T, Horikoshi H. Troglitazone and related compounds. Therapeutic potential beyond diabetes. Life Sci. 67, 2405-2416 (2000).
64. Demetri GD, Fletcher CDM, Mueller E, Sarraaf P, Naujokos R. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl Acad. Sci. 96(7), 3951-3956 (1999).
65. Neuschwander-Tetri BA, Isley WL, Oki JC. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann. Intern. Med. 129, 38-41 (1998).
66. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850 (2001).
67. Patel SR, Jenkins J, Papadopoulos NE. A pilot study of an angiogenesis inhibitor vitaxin in patients with advanced leiomyosarcomas (Leios). Am. Soc. Clin. Oncol. 19, 559 (2000).
68. Bhargava P, Marshall JL, Rizvi N, Dahut W, Figuera M. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 35, 1989-1995 (1999).
69. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr. Opin. Oncol. 12, 564 (2000).